速递｜13亿美元！礼来拿下英伟达投资AI发现的新口服减肥药

Core Viewpoint - Eli Lilly (LLY.N) has entered a $1.3 billion collaboration with privately held Superluminal Medicines to utilize artificial intelligence for discovering and developing small molecule drugs for obesity and other cardiometabolic diseases [2][4]. Group 1: Market Position and Growth - Eli Lilly currently holds a dominant position in the rapidly growing obesity treatment market, which is expected to reach $150 billion in the next decade [2]. - The company is expanding its influence through the development of new-generation drugs, acquisitions, and collaborations [2]. Group 2: Collaboration Details - Under the agreement, Eli Lilly will gain exclusive rights to develop and commercialize candidate drugs discovered using Superluminal's proprietary AI platform, focusing on G protein-coupled receptors (GPCRs) [4]. - Superluminal is also eligible for upfront payments, milestone payments, equity investments, and tiered royalties based on sales [8]. Group 3: Competitive Landscape - Several pharmaceutical companies, including Danish competitor Novo Nordisk (NOVOb.CO), are exploring GPCR targets to develop oral small molecule obesity treatments [5]. - Eli Lilly is solidifying its leading position in the GLP-1 drug category, with its best-selling drug Zepbound and Novo Nordisk's Wegovy both belonging to this class [6]. Group 4: Research and Development - Eli Lilly is developing an oral GLP-1 drug, orforglipron, although its performance has not met investor expectations [6]. - Superluminal is developing its own core candidate drug targeting the melanocortin-4 receptor (MC4R) for treating certain rare genetic obesity conditions, expected to enter human clinical trials in Q4 next year [8].